研究单位：[1]Sun Yat-sen University,Nanjing Leads Biolabs Co.,Ltd[2]Fujian Cancer Hospital,Fuzhou 1810821,Fujian 1811017,China,350014[3]Sun Yat-sen University Cancer Center,Guangzhou 1809858,Guangdong 1809935,China,510060[4]Guangxi Medical University Cancer Hospital,Nanning 1799869,Guangxi 1809867,China,530021[5]Harbin Medical University Cancer Hospital,Harbin 2037013,Heilongjiang 2036965,China,150081[6]The First Affiliated Hospital of Henan University of Science & Technology,Luoyang 1801792,Henan 1808520,China,471023[7]Henan Cancer Hospital,Zhengzhou 1784658,Henan 1808520,China,450003[8]Xiangyang Central Hospital,Xiangyang 1790587,Hubei 1806949,China,441106[9]Liaoning Cancer Hospital and Institute,Shenyang 2034937,Liaoning 2036115,China,110167[10]Shandong Cancer Hospital,Jinan 1805753,Shandong 1796328,China,250117[11]First Hospital of Shanxi Medical University,Taiyuan 1793511,Shanxi 1795912,China,030012[12]Sichuan Cancer Hospital,Chengdu 1815286,Sichuan 1794299,China,610041[13]Mianyang Central Hospital,Mianyang 1800627,Sichuan 1794299,China,621000
研究目的：
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
